Ardelyx, Inc. (ARDX)
3.80
+0.04
(+1.06%)
USD |
NASDAQ |
Sep 02, 16:00
3.79
-0.01
(-0.26%)
After-Hours: 20:00
Ardelyx Research and Development Expense (Annual) : 68.47M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 68.47M |
| December 31, 2024 | 50.25M |
| December 31, 2023 | 34.24M |
| December 31, 2022 | 34.06M |
| December 31, 2021 | 89.70M |
| December 31, 2020 | 63.23M |
| December 31, 2019 | 69.18M |
| Date | Value |
|---|---|
| December 31, 2018 | 69.37M |
| December 31, 2017 | 75.48M |
| December 31, 2016 | 94.16M |
| December 31, 2015 | 39.88M |
| December 31, 2014 | 25.90M |
| December 31, 2013 | 28.09M |
| December 31, 2012 | 10.18M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| REGENXBIO, Inc. | 212.68M |
| ACADIA Pharmaceuticals, Inc. | 328.80M |
| Alnylam Pharmaceuticals, Inc. | 1.320B |
| Anika Therapeutics, Inc. | 25.77M |
| Savara, Inc. | 81.40M |